Assembly Biosciences Inc V7B

Morningstar Rating
€13.30 −0.25 (1.85%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

V7B is trading at a 668% premium.
Price
€13.62
Fair Value
€77.80
Uncertainty
Extreme
1-Star Price
€26.94
5-Star Price
€5.16
Economic Moat
Ppnj
Capital Allocation

News

Trading Information

Previous Close Price
€13.55
Day Range
€13.3013.30
52-Week Range
€14.3018.00
Bid/Ask
€12.90 / €14.10
Market Cap
€84.40 Mil
Volume/Avg
0 /

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.55
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
65

Comparables

Valuation

Metric
V7B
ATXS
BPMC
Price/Earnings (Normalized)
Price/Book Value
2.662.5417.90
Price/Sales
3.5515.69
Price/Cash Flow
Price/Earnings
V7B
ATXS
BPMC

Financial Strength

Metric
V7B
ATXS
BPMC
Quick Ratio
2.6521.673.48
Current Ratio
2.7421.873.71
Interest Coverage
−8.43
Quick Ratio
V7B
ATXS
BPMC

Profitability

Metric
V7B
ATXS
BPMC
Return on Assets (Normalized)
−43.57%−24.27%−24.11%
Return on Equity (Normalized)
−104.16%−39.29%−104.04%
Return on Invested Capital (Normalized)
−109.82%−30.47%−41.57%
Return on Assets
V7B
ATXS
BPMC

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
QzmczmtypTlczn$518.0 Bil
Vertex Pharmaceuticals Inc
VRTX
BtghxhbfVjymvjc$119.3 Bil
Regeneron Pharmaceuticals Inc
REGN
YqtwwcwqVcpnwl$114.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
TdcxynjfYhmwttl$34.9 Bil
argenx SE ADR
ARGX
QxtwbmwbTzdm$32.9 Bil
BioNTech SE ADR
BNTX
JnvhyhlfPbm$28.3 Bil
Moderna Inc
MRNA
GcqfpdcHpjhl$24.3 Bil
United Therapeutics Corp
UTHR
SyfndhrFvrg$15.7 Bil
Biomarin Pharmaceutical Inc
BMRN
WrlcbkxPdzskq$13.3 Bil
Incyte Corp
INCY
NnbhppvbgMstfxk$13.0 Bil

Sponsor Center